{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Streptonigrin",
  "nciThesaurus": {
    "casRegistry": "3930-19-6",
    "chebiId": "CHEBI:9287",
    "chemicalFormula": "C25H22N4O8",
    "definition": "An aminoquinone antineoplastic antibiotic isolated from the bacterium Streptomyces flocculus.  Streptonigrin complexes with DNA and topoisomerase II, resulting in DNA cleavage and inhibition of DNA replication and RNA synthesis.  This agent also acts as a reverse transcriptase inhibitor and causes free radical-mediated cellular damage.",
    "fdaUniiCode": "261Q3JB310",
    "identifier": "C844",
    "preferredName": "Streptonigrin",
    "semanticType": "Antibiotic",
    "subclassOf": [
      "C259"
    ],
    "synonyms": [
      "5-Amino-6-(7-amino-5,8-dihydro-6-methoxy-5,8-dioxo-2-quinolyl)-4-(2-hydroxy-3,4-dimethoxyphenyl)-3-methyl-2-pyridinecarboxylic Acid",
      "5-Amino-6-(70-amino-5,8-dihydro-6-methoxy-5,8-dioxo-2-quinolyl)-4-(2-hydroxy-3,4-dimethoxyphenyl)-3-methylpicolinic Acid",
      "BA-163",
      "Bruneomycin",
      "PC-501",
      "Rufocromomycin",
      "STN",
      "STREPTONIGRIN",
      "Streptonigrin"
    ]
  }
}